Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Clinical trial NCT01004380 · COMPLETED

Trial details

NCT number: NCT01004380
Sponsor: Morphotek
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer

Start date: 2009-11-01
Primary completion: 2012-08-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.